Literature DB >> 17690954

The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2006.

Donn M Stewart1, Fabio Candotti, David L Nelson.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency disease caused by mutations in the Wiskott-Aldrich Protein (WASP) gene, which typically leads to absent WASP protein expression in WAS leukocytes. However, some patients have been found with small populations of WASP-expressing cells caused by reverse or second-site mutations that allow protein expression. An international consortium was established to further investigate these phenomena. This paper summarizes data collected by this consortium that was presented at a workshop held during the XIIth Meeting of the European Society for Immunodeficiencies (ESID), October, 2006. WASP reversions were noted in approximately 11% of 272 patients tested. Many different cell lineages showed reversions. These data form the foundation for further investigation into this phenomenon, which has implications for therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690954     DOI: 10.1007/s10875-007-9121-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  23 in total

1.  Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers.

Authors:  M Yamada; M Ohtsu; I Kobayashi; N Kawamura; K Kobayashi; T Ariga; Y Sakiyama; D L Nelson; S Tsuruta; M Anakura; N Ishikawa
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

2.  Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.

Authors:  V Stephan; V Wahn; F Le Deist; U Dirksen; B Broker; I Müller-Fleckenstein; G Horneff; H Schroten; A Fischer; G de Saint Basile
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

3.  Somatic revertant mosaicism in a patient with leukocyte adhesion deficiency type 1.

Authors:  Yumi Tone; Taizo Wada; Fumie Shibata; Tomoko Toma; Yoko Hashida; Yoshihito Kasahara; Shoichi Koizumi; Akihiro Yachie
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

4.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

6.  Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome.

Authors:  Maxim I Lutskiy; Diana S Beardsley; Fred S Rosen; Eileen Remold-O'Donnell
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

7.  X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival.

Authors:  Ryuta Nishikomori; Hiroshi Akutagawa; Kyoko Maruyama; Mami Nakata-Hizume; Katsuyuki Ohmori; Kazunori Mizuno; Akihiro Yachie; Takahiro Yasumi; Takashi Kusunoki; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

8.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

9.  Self-induced correction of the genetic defect in tyrosinemia type I.

Authors:  E A Kvittingen; H Rootwelt; R Berger; P Brandtzaeg
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

10.  A second-site mutation in the initiation codon of WAS (WASP) results in expansion of subsets of lymphocytes in an Wiskott-Aldrich syndrome patient.

Authors:  Wei Du; Satoru Kumaki; Toru Uchiyama; Akihiro Yachie; Chung Yeng Looi; Shin Kawai; Masayoshi Minegishi; Narayanaswamy Ramesh; Raif S Geha; Yoji Sasahara; Shigeru Tsuchiya
Journal:  Hum Mutat       Date:  2006-04       Impact factor: 4.878

View more
  16 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

3.  WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.

Authors:  Lisa S Westerberg; Miguel A de la Fuente; Fredrik Wermeling; Hans D Ochs; Mikael C I Karlsson; Scott B Snapper; Luigi D Notarangelo
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

Review 4.  Laboratory diagnosis of primary immunodeficiencies.

Authors:  Bradley A Locke; Trivikram Dasu; James W Verbsky
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

Review 5.  Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment.

Authors:  Sung-Yun Pai; Luigi D Notarangelo
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

6.  Revertant somatic mosaicism in the Wiskott-Aldrich syndrome.

Authors:  Brian R Davis; Fabio Candotti
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

7.  Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.

Authors:  Francesco Marangoni; Marita Bosticardo; Sabine Charrier; Elena Draghici; Michela Locci; Samantha Scaramuzza; Cristina Panaroni; Maurilio Ponzoni; Francesca Sanvito; Claudio Doglioni; Marie Liabeuf; Bernard Gjata; Marie Montus; Katherine Siminovitch; Alessandro Aiuti; Luigi Naldini; Loïc Dupré; Maria Grazia Roncarolo; Anne Galy; Anna Villa
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

Review 8.  Somatic genetic rescue in Mendelian haematopoietic diseases.

Authors:  Patrick Revy; Caroline Kannengiesser; Alain Fischer
Journal:  Nat Rev Genet       Date:  2019-06-11       Impact factor: 53.242

9.  Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus.

Authors:  Umaimainthan Palendira; Carol Low; Andrew I Bell; Cindy S Ma; Rachel J M Abbott; Tri Giang Phan; D Sean Riminton; Sharon Choo; Joanne M Smart; Vassilios Lougaris; Silvia Giliani; Rebecca H Buckley; Bodo Grimbacher; Frank Alvaro; Amy D Klion; Kim E Nichols; Stephen Adelstein; Alan B Rickinson; Stuart G Tangye
Journal:  J Exp Med       Date:  2012-04-09       Impact factor: 14.307

10.  Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma.

Authors:  Marco Catucci; Maria Carmina Castiello; Francesca Pala; Marita Bosticardo; Anna Villa
Journal:  Front Immunol       Date:  2012-07-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.